Owlet’s FDA-cleared “smart sock” pivot turns a baby gadget into a regulated MedTech platform—unlocking reimbursement and subscriptions, but demanding perfect execution.
Overview
Owlet has reached an inflection point by completing a strategic pivot from consumer baby electronics to an FDA-cleared medical device company spanning connected health and DME. The FDA De Novo-cleared Dream Sock is positioned as the first and only OTC infant pulse oximeter, enabling differentiated health claims and creating a regulatory moat versus camera-based wellness rivals. BabySat extends the platform into prescription monitoring for medically fragile infants, enabling entry into reimbursement-driven healthcare distribution. Q3 2025 validated the “Medical Pulse” strategy with record revenue ($32.0M, +44.6% YoY), the sixth consecutive quarter of positive Adjusted EBITDA ($1.6M), and the first quarterly operating profit—evidence that prior cost restructuring and supply-chain optimization are working despite tariff headwinds. The go-forward plan diversifies away from pure DTC/retail into B2B2C healthcare via DME partnerships and builds recurring revenue through Owlet360 subscriptions. Key offsets to the opportunity include heavy competition (Masimo, Nanit), a still-delicate balance sheet (cash roughly matched by debt), and meaningful execution risk in scaling reimbursement and subscription economics.